PUBLISHER: BIS Research | PRODUCT CODE: 1413711
PUBLISHER: BIS Research | PRODUCT CODE: 1413711
Europe Next-Generation Breast Cancer Diagnostic and Screening Market: Analysis and Forecast, 2023-2032
“The Europe Next-Generation Breast Cancer Diagnostic and Screening Market Expected to Reach $2.57 Billion by 2032.”
Introduction to Europe Next-Generation Breast Cancer Diagnostic and Screening Market
The Europe next-generation breast cancer diagnostic and screening market was valued at $0.84 billion in 2023 and is expected to reach $2.57 billion by the end of 2032, registering a CAGR of 13.20% during the forecast period 2023-2032. The growth in the next-generation breast cancer diagnostic and screening market is expected to be driven by the increase in the prevalence of breast cancer cases, rising awareness regarding early diagnosis of breast cancer, growing focus on breast cancer biomarkers for effective screening, prognosis, and personalized treatment, and increasing partnerships and collaborations amongst market players.
| KEY MARKET STATISTICS | |
|---|---|
| Forecast Period | 2023 - 2032 |
| 2023 Evaluation | $0.84 Billion |
| 2032 Forecast | $2.57 Billion |
| CAGR | 13.2% |
Market Introduction
The European Next-Generation Breast Cancer Diagnostic and Screening Market is experiencing significant growth driven by factors such as the region's early adoption of advanced medical technologies, a high prevalence of breast cancer, and a strong healthcare infrastructure. European countries prioritize breast cancer awareness and screening, fostering the integration of innovative biomarkers and genetic testing into diagnosis. Collaborations between healthcare institutions, research organizations, and industry players further enhance diagnostic accuracy and efficiency, contributing to improved patient outcomes. These efforts reflect the region's commitment to addressing breast cancer challenges and are expected to sustain market growth and enhance breast cancer management in Europe.
Market Segmentation:
Segmentation 1: by Country
- Germany
- France
- U.K.
- Italy
- Spain
- Rest-of-Europe
How can this report add value to an organization?
Growth/Marketing Strategy: The Europe next-generation breast cancer diagnostic and screening market has seen major development by key players operating in the market, such as business expansions, partnerships, collaborations, mergers and acquisitions, product launches, and funding activities. Partnerships, alliances, and business expansions accounted for the maximum number of key developments in the Europe next-generation breast cancer diagnostic and screening market, followed by regulatory and legal activities and mergers and acquisitions.
Competitive Strategy: Key players in the Europe next-generation breast cancer diagnostic and screening market analyzed and profiled in the study involve players that offer next-generation breast cancer diagnostic and screening products and services. Moreover, comprehensive competitive strategies such as partnerships, agreements, collaborations, product launches and approvals, and funding scenarios will aid the reader in understanding the untapped revenue pockets in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.
Some of the prominent names in this market are:
|
|
Table of Contents
Executive Summary
Scope of the Study
Research Methodology
1. Oncology Molecular Diagnostic Market
- 1.1. Overview
- 1.2. Cancer Type
- 1.3. Technology
- 1.4. Market Dynamics
- 1.5. Regulatory-Approved Products
2. Regions
- 2.1. Europe
- 2.1.1. Key Findings
- 2.1.2. Market Dynamics
- 2.1.2.1. Impact Analysis
- 2.1.3. Market Sizing and Forecast
- 2.1.3.1. Europe Next-Generation Breast Cancer Diagnostic and Screening Market (by Country)
- 2.1.3.1.1. Germany
- 2.1.3.1.1.1. Market Dynamics
- 2.1.3.1.1.2. Market Sizing and Forecast
- 2.1.3.1.2. France
- 2.1.3.1.2.1. Market Dynamics
- 2.1.3.1.2.2. Market Sizing and Forecast
- 2.1.3.1.3. U.K.
- 2.1.3.1.3.1. Market Dynamics
- 2.1.3.1.3.2. Market Sizing and Forecast
- 2.1.3.1.4. Italy
- 2.1.3.1.4.1. Market Dynamics
- 2.1.3.1.4.2. Market Sizing and Forecast
- 2.1.3.1.5. Spain
- 2.1.3.1.5.1. Market Dynamics
- 2.1.3.1.5.2. Market Sizing and Forecast
- 2.1.3.1.6. Rest-of-Europe
- 2.1.3.1.6.1. Market Dynamics
- 2.1.3.1.6.2. Market Sizing and Forecast
- 2.1.3.1.1. Germany
- 2.1.3.1. Europe Next-Generation Breast Cancer Diagnostic and Screening Market (by Country)
3. Markets - Competitive Benchmarking
- 3.1. Next-Generation Breast Cancer Diagnostic and Screening Active Players Ecosystem
- 3.2. Company Profiles
- 3.2.1. Agendia Inc.
- 3.2.1.1. Company Overview
- 3.2.1.2. Role of Agendia Inc. in the Next-Generation Breast Cancer Diagnostic and Screening Market
- 3.2.1.3. Recent Developments
- 3.2.1.4. Analyst Perception
- 3.2.2. CENTOGENE N.V.
- 3.2.2.1. Company Overview
- 3.2.2.2. Role of CENTOGENE N.V. in the Next-Generation Breast Cancer Diagnostic and Screening Market
- 3.2.2.3. Financials
- 3.2.2.4. Recent Developments
- 3.2.2.5. Analyst Perception
- 3.2.3. F. Hoffmann-La Roche Ltd.
- 3.2.3.1. Company Overview
- 3.2.3.2. Role of F. Hoffmann-La Roche Ltd. in the Next-Generation Breast Cancer Diagnostic and Screening Market
- 3.2.3.3. Financials
- 3.2.3.4. Recent Developments
- 3.2.3.5. Analyst Perception
- 3.2.1. Agendia Inc.
List of Figures
- Figure 1: Worldwide Breast Cancer Statistics (by Region), 2020
- Figure 2: Europe Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 3: Next-Generation Breast Cancer Diagnostic and Screening Market (by Region), $Million, 2022 and 2032
- Figure 4: Next-Generation Breast Cancer Diagnostic and Screening Market, Impact Analysis
- Figure 5: Next-Generation Breast Cancer Diagnostic and Screening Market, Key Development Analysis, January 2019-April 2023
- Figure 6: Next-Generation Breast Cancer Diagnostic and Screening Market: Research Methodology
- Figure 7: Primary Research Methodology
- Figure 8: Bottom-Up Approach (Segment-Wise Analysis)
- Figure 9: Top-Down Approach (Segment-Wise Analysis)
- Figure 10: Oncology Molecular Diagnostic Market, Solid Tumor, $Million, 2022 and 2032
- Figure 11: Oncology Molecular Diagnostic Market, Hematological Malignancy, $Million, 2022 and 2032
- Figure 12: Oncology Molecular Diagnostic Market, Market Dynamics
- Figure 13: Next-Generation Breast Cancer Diagnostic and Screening Market Share (by Region), 2022-2032
- Figure 14: Europe Next-Generation Breast Cancer Diagnostic and Screening Market, Incremental Opportunity (by Country), $Million, 2023-2032
- Figure 15: Europe Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 16: Europe Next-Generation Breast Cancer Diagnostic and Screening Market (by Country), Share (%), 2022 and 2032
- Figure 17: Germany Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 18: France Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 19: U.K. Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 20: Italy Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 21: Spain Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 22: Rest-of-Europe Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
- Figure 23: Agendia Inc.: Product Portfolio
- Figure 24: CENTOGENE N.V.: Product Portfolio
- Figure 25: CENTOGENE N.V.: Overall Financials, $Million, 2019-2021
- Figure 26: CENTOGENE N.V.: Net Revenue (by Segment), $Million, 2019-2021
- Figure 27: CENTOGENE N.V.: Net Revenue (by Region), $Million, 2019-2021
- Figure 28: CENTOGENE N.V.: R&D Expenditure, $Million, 2019-2021
- Figure 29: F. Hoffmann-La Roche Ltd.: Product Portfolio
- Figure 30: F. Hoffmann-La Roche Ltd.: Overall Financials, $Million, 2020-2022
- Figure 31: F. Hoffmann-La Roche Ltd.: Net Revenue (by Segment), $Million, 2020-2022
- Figure 32: F. Hoffmann-La Roche Ltd.: R&D Expenditure, $Million, 2020-2022
List of Tables
- Table 1: Key Questions Answered in the Report
- Table 2: Some of the Regulatory-Approved Oncology Molecular Diagnostic Products/Services for Different Types of Solid Tumors
- Table 3: Europe Next-Generation Breast Cancer Diagnostic and Screening Market, Impact Analysis
- Table 4: Next-Generation Breast Cancer Diagnostic and Screening Active Players Ecosystem
- Table 5: Agendia Inc.: Key Services and Features
- Table 6: CENTOGENE N.V.: Key Services and Features
- Table 7: F. Hoffmann-La Roche Ltd.: Key Products and Features
